摘要
目的 观察紫杉醇脂质体和紫杉醇分别联合顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应.方法 将50例晚期非小细胞肺癌患者随机分为试验组和对照组,每组各25例.试验组：紫杉醇脂质体150 mg/m2第1天＋顺铂25 mg/m2第1-3天;对照组：紫杉醇150 mg/m2＋顺铂25 mg/m2第1-3天,化疗每21天为1个周期.结果 试验组和对照组客观有效率（RR）分别为44.0％和40.0％,临床获益率（CBR）分别为80.0％和72.0％,两组RR和CBR比较差异无统计学意义（P=0.774,0.508）.试验组的无进展生存时间（PFS）为5.6个月,对照组为4.9个月,两组比较差异无统计学意义（P=0.126）.试验组恶心、呕吐,肌肉关节痛,过敏反应及末梢神经炎的发生率显著低于对照组,两组比较差异有统计学意义（P均＜0.05）;试验组和对照组的腹泻、白细胞下降、贫血、血小板下降、脱发及肝功损伤的发生率比较差异无统计学意义（P均＞0.05）.结论 紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌与紫杉醇联合顺铂疗效相当,但不良反应发生率降低.
Objective： To observe the clinical efficacy and adverse reactions between paclitaxel liposorne plus cisplatinand paelitaxel plus eisplatin in the treatment of advanced non - small cell lung cancer（ NSCLC ）. Methods： Totally 50 pa-tients with NSCLC were randomly assigned into experimental group and control group. In the experimental group, paclitaxelliposome was injected on day I at a dosage of 150 mg/rn2 and cisplatin was injected on day 1- 3 at a dosage of25mg/m2,the same dose and administration with paclitaxel and cisplatin in the control group, every 21 days for a chemotherapy cycle.Results： In the experimental group and the control group, the objective response rate （RR） and clinical benefit rate（CBR） were 44. 0% vs. 40. 0%, 80.0% vs. 72. 0%, respectively, there were no statistically significant difference be-tween two groups （ P = 0. 774,0. 508）. Progression - free survival time （PFS） in the experimental group was 5.6 monthsand 4. 9 months in the control group, there was aslo no statistically significant difference between two groups （P = 0. 126）.The incidence of nausea, vomiting, muscle and joint pain, allergic reactions and peripheral neuritis in the experimentalgroup were significantly lower than the control group （ P 〈 0. 05 ）. There were no statistically significant difference in diar-rhea, leukopenia, anemia, thrombocytopenia, alopecia and liver injury between two groups （ P 〉 0.05 ） Conclusion The pa-clitaxel liposome plus cisplatin is as effective as paclitaxel plus cisplatin in the treatment of NSCLC, but paclitaxel liposomeplus cisplatin has less adverse reactions than paclitaxel plus cisplatin.
出处
《泰山医学院学报》
CAS
2015年第8期871-874,共4页
Journal of Taishan Medical College
关键词
紫杉醇脂质体
紫杉醇
非小细胞肺癌
顺铂
paclitaxel liposome
paclitaxel
non - small cell lung cancer
cisplatin
作者简介
孙银萍（1971-），女，山东淄博人，主治医师，硕士，主要从事肺癌的化疗及分子靶向治疗工作。
